Biosig Technologies Inc

BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. Its product PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intra-cardiac signals for patients undergoing electrophysiology procedures. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Westport, CT, July  30, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will present at the Proactive Investors One2One Virtual Event on August 4, 2020.

BioSig Technologies to Present at the Proactive Investors One2One Virtual Event on August 4, 2020

Chairman and CEO Kenneth L. Londoner to provide an update on the commercial rollout of PURE EP(tm) System, clinical development of BioSig’s pharmaceutical subsidiary and conduct virtual one-on-one meetings with investors Chairman and CEO Kenneth L. Londoner to provide an update on the commercial rollout of PURE EP(tm) System, clinical development of BioSig’s pharmaceutical subsidiary and conduct virtual one-on-one meetings with investors

BioSig Technologies to Participate in LD Micro’s Zooming with LD

Westport, CT, July  20, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced the formation of its Scientific Advisory Board (SAB). The SAB will review all aspects of drug discovery and development and will advise the company on its mission to control emerging infections and viral diseases of special interest including COVID-19.

ViralClear Announces Formation of Its Scientific Advisory Board

ViralClear Chief Medical Officer Dr. Jerry Zeldis to Speak on Panel Titled “Arresting the Viral Replication Cycle” at B Riley FBR’s Infectious Disease Summit ViralClear Chief Medical Officer Dr. Jerry Zeldis to Speak on Panel Titled “Arresting the Viral Replication Cycle” at B Riley FBR’s Infectious Disease Summit

BioSig Technologies to Participate in the B Riley FBR Virtual Infectious Disease Summit

Westport, CT, July  16, 2020  (GLOBE NEWSWIRE) -- Amended

BioSig Technologies, Inc. Adopts Stockholder Rights Agreement

BioCryst Pharmaceuticals

BioNTech SE

CytoDyn Inc.

Eiger BioPharmaceuticals

Gilead Sciences

Immunic Inc

Pfizer

Regeneron Pharmaceuticals

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Antivirals In The COVID-19 Space

Adult patients hospitalized with COVID-19 are enrolled in Austin, TX, Rochester, MN, Jacksonville, FL, and Scottsdale, AZ Adult patients hospitalized with COVID-19 are enrolled in Austin, TX, Rochester, MN, Jacksonville, FL, and Scottsdale, AZ

Phase II Human Trial of ViralClear's Anti-Viral for SARS-CoV-2 Coronavirus Underway at 4 Key Trial Sites

Registration would provide Company access to business with the federal government, including contract and grant opportunities Registration would provide Company access to business with the federal government, including contract and grant opportunities

BioSig Submits Application to Systems for Award Management (SAM) with U.S. Government

Westport, CT, July  08, 2020  (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it is partnering with  Albany Molecular Research Inc. , (AMRI), a leading global contract research, development and manufacturing organization (CDMO), for support in undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a standalone treatment or in combination with other anti-viral agents or immune modulators.

ViralClear Pharmaceuticals partners with Albany Molecular Research Inc. on the manufacture of merimepodib active pharmaceutical ingredient development for the potential treatment of COVID-19

Former President and CEO of the North American division of AstraZeneca Plc to join as Independent Director Former President and CEO of the North American division of AstraZeneca Plc to join as Independent Director

BioSig Technologies Inc. Appoints Tony Zook to the Board of Directors

Westport, CT, June  29, 2020  (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority-owned subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it has closed on the sale of 2,187,500 shares of the Company’s common stock, at a purchase price of $8.00 per share, in a registered direct offering. The closing of the offering occurred on June 26, 2020.

BioSig Technologies, Inc Closes $17.5 Million Common Stock Offering

The company announced a common stock offering.

Why BioSig Technologies Is Plunging Today

Westport, CT, June  24, 2020  (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 2,187,500 shares of the Company’s common stock, at a purchase price of $8.00 per share, in a registered direct offering. The closing of the offering is expected to occur on or about June 26, 2020, subject to the satisfaction of customary closing conditions.

BioSig Technologies, Inc. Announces $17.5 Million Common Stock Only Registered Direct Offering

Westport, CT, June  22, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc.  (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced that it has signed an agreement with Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, to work on the development of a potential treatment for adults with advanced Coronavirus Disease 2019 (COVID-19).

ViralClear Partners with Catalent on Potential Treatment for COVID-19

Initiation of randomized, double-blind, placebo-controlled Phase II trial of merimepodib, an orally administered broad-spectrum anti-viral, in combination with intravenous remdesivir in patients with advanced COVID-19 (hospitalized and requiring  oxygen) Initiation of randomized, double-blind, placebo-controlled Phase II trial of merimepodib, an orally administered broad-spectrum anti-viral, in combination with intravenous remdesivir in patients with advanced COVID-19 (hospitalized and requiring  oxygen)

ViralClear Opens Enrollment with First Patient Dosing in Phase II Human Trial of Anti-Viral MMPD Oral Solution for Treatment of COVID-19

BioSig Technologies, Inc. (BSGM) CEO Ken Londoner on Phase II Human Trials for Broad-Spectrum Oral Anti-Viral for Treatment of COVID-19 (Transcript)

Randomized, double-blind, placebo-controlled Phase II trial of merimepodib to be conducted in adults with COVID-19 who are hospitalized and require supplemental oxygen or are on non-invasive ventilation or high-flow oxygen devices Randomized, double-blind, placebo-controlled Phase II trial of merimepodib to be conducted in adults with COVID-19 who are hospitalized and require supplemental oxygen or are on non-invasive ventilation or high-flow oxygen devices

ViralClear adds St. David's HealthCare in Austin, Texas,  to its Planned Phase II trial for its Broad-Spectrum Oral Anti-Viral Candidate for COVID-19

Company’s flagship biomedical signal processing platform highlighted in two scientific sessions presented by key opinion leaders from Mayo Clinic Company’s flagship biomedical signal processing platform highlighted in two scientific sessions presented by key opinion leaders from Mayo Clinic

BioSig Technologies’s PURE EP System to be Presented in Heart Rhythm Society 2020 Science Sessions

Westport, CT, June  03, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,645,017 titled “Systems, Apparatus and Methods for Conveying Biomedical Signals between a Patient and Monitoring and Treatment Devices,” which is intended to broadly protect the Company’s flagship product – the PURE EP(tm) System. 

BioSig Technologies Expands Intellectual Property Portfolio

Pharmaceutical industry leader to join as the Company prepares for the Phase II clinical trial with merimepodib, an orally administered broad-spectrum anti-viral for COVID-19 Pharmaceutical industry leader to join as the Company prepares for the Phase II clinical trial with merimepodib, an orally administered broad-spectrum anti-viral for COVID-19

Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

Westport, CT, May  20, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced the closing of a $10.8 million common stock financing. ViralClear plans to use the proceeds of this offering for the development, including phase II human clinical trials, of its product candidate merimepodib, a broad-spectrum anti-viral agent. The financing was completed at a $100 million pre-money valuation.

ViralClear Closes $10.8 Million Equity Financing for Development of  COVID-19 Broad-Spectrum Oral Anti-Viral Candidate Merimepodib

Westport, CT, May  18, 2020  (GLOBE NEWSWIRE) --   BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced that the U.S. Food and Drug Administration (FDA) has completed its review of ViralClear’s Investigational New Drug (IND) application. The FDA informed ViralClear that it may proceed with a proposed phase II study of merimepodib oral solution in adults with COVID-19 who are hospitalized and either require supplemental oxygen or are on non-invasive ventilation or high flow oxygen devices.

FDA Clears the Investigational New Drug Application to Enable the Phase II Trial of ViralClear’s Merimepodib, Oral Solution to Treat Adult Patients with Advanced COVID-19, to Proceed

Pharmaceutical expert and Chairman of PTC Therapeutics joins other biotech leaders as Independent Director Pharmaceutical expert and Chairman of PTC Therapeutics joins other biotech leaders as Independent Director

Michael Schmertzler Joins the Board of ViralClear Pharmaceuticals, a Majority-Owned Subsidiary of BioSig Technologies, Inc.

Founder of Aisling Capital, Mr. Purcell was honored in the ‘Biotech Hall of Fame’ and cited as one of the top 100 contributors to the biotechnology sector Founder of Aisling Capital, Mr. Purcell was honored in the ‘Biotech Hall of Fame’ and cited as one of the top 100 contributors to the biotechnology sector

Biotech and Investment Veteran Dennis Purcell Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.

You've probably heard by now of Gilead's promising COVID-19 drug, remdesivir. But there's another experimental drug that just might capture investors' attention in the near future.

News for Biosig Technologies Inc Stock (BSGM)